NCT00528242View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Raynaud's Disease
Interventions
DRUG

SLx-2101

DRUG

Placebo

Trial Locations (1)

Unknown

University des Saarlandes, Homburg

Sponsors
All Listed Sponsors
lead

Response Pharmaceuticals

INDUSTRY

NCT00528242 - Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease | Biotech Hunter | Biotech Hunter